Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Methotrexate
100%
Rheumatoid Arthritis Treatment
100%
T2T Strategy
100%
Biological Disease-modifying Antirheumatic Drugs (bDMARDs)
100%
Non-biological
33%
Disease Activity
22%
High Disease Activity
22%
Nonparametric Test
22%
Moderate Disease Activity
22%
Monotherapy
11%
Exposure Groups
11%
Disease Severity
11%
Remission
11%
Severe Disease
11%
Treatment Group
11%
Treatment Effect
11%
Wilcoxon
11%
Leflunomide
11%
Sulfasalazine
11%
Chloroquine
11%
Tender Joint Count
11%
Retrospective Cohort
11%
6-month Follow-up
11%
Swollen Joint Count
11%
Disease Activity Score
11%
Prednisolone
11%
Moderate Disease
11%
Treat-to-target
11%
Clinimetrics
11%
Paired Data
11%
Health Assessment Questionnaire
11%
Inpatient Treatment
11%
Severity Levels
11%
Disease Activity Score 28 (DAS28)
11%
Medicine and Dentistry
Methotrexate
100%
Cohort Analysis
100%
Inflammatory Arthritis
100%
Rheumatoid Arthritis
100%
Disease Modifying Antirheumatic Drug
100%
Disease Activity
66%
Nonparametric Test
22%
DAS28
11%
Leflunomide
11%
Chloroquine
11%
Salazosulfapyridine
11%
Monotherapy
11%
Treatment Group
11%
Disease Activity Score
11%
Health Assessment Questionnaire
11%
Prednisolone
11%
Clinimetrics
11%
Pharmacology, Toxicology and Pharmaceutical Science
Rheumatoid Arthritis
100%
Inflammatory Arthritis
100%
Cohort Study
100%
Disease Modifying Antirheumatic Drug
100%
Methotrexate
100%
Disease Activity
66%
Monotherapy
11%
Remission
11%
Sulfasalazine
11%
Chloroquine
11%
Leflunomide
11%
Treatment Group
11%
Disease Activity Score
11%
Prednisolone
11%
Neuroscience
Rheumatoid Arthritis
100%
Methotrexate
100%
Disease-Modifying Antirheumatic Drug
100%
Sulfasalazine
11%
Prednisolone
11%
Chloroquine
11%
Leflunomide
11%
Immunology and Microbiology
Inflammatory Arthritis
100%
Methotrexate
100%
Disease-Modifying Antirheumatic Drug
100%
Leflunomide
11%
Chloroquine
11%
Sulfasalazine
11%
Prednisolone
11%